Main Content
latest…
Cresco Labs’ deal for Origin House is looking sweeter, says GMP Securities
In a flash update to clients on Friday, GMP Securities analyst Robert Fagan reiterated his “Buy” … Keep reading
More recent headlines
Cannabis
Cresco Labs’ deal for Origin House is looking sweeter, says GMP Securities
In a flash update to clients on Friday, GMP Securities analyst Robert Fagan reiterated his “Buy” rating and $21.50 target price for US cannabis play … Read More
See related
Stock Picks
Take a pass on Extendicare, says Echelon Wealth
Expecting profit margins to grow by the end of 2019, Echelon Wealth Partners analyst Douglas Loe is upping his forecast on long-term care and extended … Read more
See related
Life Sciences Stocks
Buy Theratechnologies for its HIV franchise, Echelon Wealth says
Earlier this year, Endocrinology drug developer Theratechnologies (Theratechnologies Stock Quote, … Keep reading
Zymeworks has a 69 per cent upside, says Paradigm Capital
Clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart TSX, NYSE:ZYME) has … Keep reading
Take pass on Knight Therapeutics for now, Mackie Research says
It’s still early innings for Knight Therapeutics (Knight Therapeutics Stock Quote, Chart TSX:GUD), … Keep reading
Correvio Pharma has major catalysts on the horizon, Mackie says
Mackie Research analyst André Uddin is sticking to his guns when it comes to specialty … Keep reading
Protech Home Medical won’t be ruined by cyber theft, Beacon says
Protech Home Medical (Protech Home Medical Stock Quote, Chart TSXV:PTQ) has become victim of a … Keep reading
